Loading…
Change Tracker · re-verified every quarter
When a payer pushes white bagging, the first question is whether your state lets them. This tracker classifies all 50 states + DC — 11 bans, 11 guardrails, 6 live bills — with every statute cited to its primary text and dated. Below the map: the four national payer programs, translated to what they actually mean for office buy-and-bill.
AMA materials count 12 states; the most-circulated industry chart is a January-2024 PDF that predates five of the current bans; and several widely-copied statute citations are simply wrong — we verified every cite against the enacted text and corrected five of them (listed below). The honest picture: 11 enacted bans of varying scope (Arkansas is hem/onc-only, Oregon is oncology-only, Texas triggers on condition categories), 11 partial guardrails, and a live 2026 wave of bills — with one widely-miscounted near-miss in Missouri (corrected below).
Click a state tile to jump to its row and citation.
Payers/PBMs cannot mandate white bagging or refuse to pay for provider-acquired clinician-administered drugs (scope varies — see notes).
| State | Statute | Year | What it actually does |
|---|---|---|---|
| Alaska | Alaska Stat. §21.27.951 | 2024 | Insurers/PBMs may not refuse to authorize, approve, or pay for covered clinician-administered drugs sourced outside their network pharmacy. Effective Jan 1, 2025. |
| Arkansas | Ark. Code §§23-99-1401–1404 | 2021 | "Billing in the Best Interest of Patients Act" — payer must reimburse drug + administration per the provider's billing choice. Hematology/oncology diagnoses only (commissioner may expand). |
| Louisiana | La. R.S. 22:1020.51–.53 | 2021 | Insurers/PBMs may not refuse to authorize, approve, or pay participating providers for covered physician-administered drugs sourced outside designated pharmacies; payment at contract rate, no extra patient fees (Act 358). |
| Mississippi | 2025 Miss. Laws, HB 17 | 2025 | Insurers/PBMs may not refuse to authorize, approve, or pay participating providers for covered physician-administered drugs (contract rate or WAC), effective July 1, 2025; violations are consumer-protection violations. |
| North Dakota | N.D. Cent. Code §19-02.1-16.6 | 2023 | PBMs/payers may not mandate designated-pharmacy dispensing to a care site or patient (bans white- AND brown-bag mandates), nor condition or cut provider payment for non-PBM-affiliated sourcing. |
| Oklahoma | Okla. Stat. tit. 36, §6969 | 2024 | Plans/PBMs may not refuse to authorize, approve, or pay participating providers for covered physician-administered drugs; buy-and-bill at contract rate protected, $5,000–$10,000 per violation (emergency eff. Apr 29, 2024). |
| Oregon | 2024 Or. Laws ch. 24 (HB 4012) | 2024 | Oncology only — insurers may not mandate network/designated-pharmacy sourcing of clinician-administered cancer drugs on specified provider determinations. Effective Jan 1, 2025; most trackers miss it. |
| Rhode Island | R.I. Gen. Laws §27-18-33.3 | 2024 | Insurers may not refuse to authorize, approve, or pay in-network hospitals/clinics for dispensing + administering covered clinician-administered drugs, at the insurer's preferred-pharmacy rate. Effective Jan 1, 2025. |
| Tennessee | Tenn. Code §56-7-3120 | 2021 | Members may obtain drugs (incl. specialty) at a physician office, outpatient infusion center, or contracted pharmacy without penalties, extra fees, or steering — patient-choice framing, contracted providers only. |
| Texas | Tex. Ins. Code §§1369.761–.766 | 2023 | For chronic/complex/rare/life-threatening conditions: no network-pharmacy-only mandates for clinician-administered drugs, no coverage exclusion for outside sourcing, no forced pharmacy-benefit billing without written consent (HB 1647). |
| Vermont | 8 V.S.A. §4089j(d) | 2022 | Flat ban on insurer/PBM-mandated designated-pharmacy dispensing to a care site or to the patient for transport (white AND brown bagging). Medicaid exempt. Effective Jan 1, 2023. |
Conditions or partial limits (anti-steering, consent, brown-bag-only bans, exception processes) without a buy-and-bill guarantee.
| State | Statute | Year | What it actually does |
|---|---|---|---|
| Alabama | Ala. Code §27-45A-8 | 2021 | PBM anti-steering/pharmacy-choice law — not specific to clinician-administered drugs and no buy-and-bill protection. |
| Delaware | 24 Del. Admin. Code 2500 §5.1.5 | 2023 | Pharmacy-board rule banning brown bagging of drugs needing special storage/compounding; binds pharmacies, not payers — white-bag mandates untouched. |
| Florida | Fla. Stat. §626.8825 | 2023 | PBMs may not steer to affiliated pharmacies for physician-administered drugs and must offer onsite-administration contracts to cancer/transplant/children's centers (broadened Mar 2026) — but no general buy-and-bill guarantee. |
| Georgia | Ga. DOI Directives 22-EX-5 / 22-EX-6 | 2022 | Insurance-commissioner directives (not statute) ban white bagging at critical-access and rural hospitals only; Aetna nonetheless treats GA as a full medical-benefit carve-out state. |
| Illinois | P.A. 104-0027 (2025) | 2025 | Prescription Drug Affordability Act bans PBM self-steering and "specialty" designations that limit access — not clinician-administered-drug-specific; drafted to reach self-insured plans (ERISA litigation risk). |
| Minnesota | Minn. Stat. §62W.15 | 2023 | Mandated specialty-pharmacy dispensing must meet shipping/safety standards with a provider appeal/exception process; bans mandatory brown bagging — but does not flatly prohibit white-bag mandates. |
| Nebraska | Neb. Rev. Stat. §44-4613 | 2025 | Specialty-pharmacy mandates require an exception/appeal process; no denial of provider-stock reimbursement on cost alone when cost is similar; no penalties for refusing white-bagged product. Operative Jan 1, 2026. |
| New Mexico | 2023 N.M. Laws ch. 206 (SB 51) | 2023 | Cost-sharing parity for non-affiliated pharmacy/site sourcing — mandating a designated pharmacy is not itself prohibited. |
| Ohio | Ohio Rev. Code §4729.43; §5167.24 | 2021 | Pharmacist-side brown-bag ban for IV/SC cancer drugs + a Medicaid-PBM-only steering ban — commercial white-bag mandates remain lawful. |
| Utah | Utah Code §31A-22-658 | 2023 | Brown-bag mandates banned; classic white bagging (ship to site of care) remains permitted. |
| Virginia | Va. Code §38.2-3407.7; 18 VAC 110-20-275 | 2021 | The widely-cited weak model: pharmacy freedom-of-choice statute + a pharmacy regulation that PERMITS white bagging under a written agreement; providers report ongoing mandates. |
A live bill this session; no enacted law yet.
| State | Statute | Year | What it actually does |
|---|---|---|---|
| Arizona | SB 1710 (2026) | — | 2026 bill would bar PBM steering to affiliated pharmacies, including for office-administered drugs; not enacted. |
| Maryland | HB 1461 (2026) | — | Pending bill covers rheumatologic specialty drugs only; existing Md. Ins. Code §15-847 actually PERMITS designated-pharmacy requirements. |
| Massachusetts | H.4956 (194th Gen. Court) | — | Clinician-administered-drug patient-choice bill reported favorably to Health Care Financing, Jan 2026; not enacted. |
| New Hampshire | SB 256 (2025–26) | — | Clinician-administered-drugs bill fought through early 2026, then sent to interim study May 1, 2026 — not enacted. |
| New York | S5314 (2025–26) | — | Recurring bill would bar white bagging for drugs needing sterile compounding or same-day dosing; never passed either chamber. |
| West Virginia | HB 3067 (2025) | — | Texas-style ban bill introduced Mar 2025, parked in committee; a 2022 predecessor passed one chamber and died. |
| State | Year | What it actually does |
|---|---|---|
| California | — | No white-bagging statute; 2025's PBM law (SB 41) does not address payer-mandated sourcing of clinician-administered drugs. |
| Colorado | — | HB24-1010 (provider-administered drugs) passed both chambers and was vetoed in May 2024; no enacted replacement. |
| Connecticut | — | No statute; the issue was referred to the state's Prescription Drug Task Force. |
| District of Columbia | — | No statute or notable pending bill found. |
| Hawaii | — | No white-bagging statute. |
| Idaho | — | No statute or notable pending bill found. |
| Indiana | — | No white-bagging restriction (NICA, Feb 2026). |
| Iowa | — | 2025 PBM law (SF 383) covers retail steering, not provider-administered drug sourcing. |
| Kansas | — | No white-bagging law (NICA, Feb 2026). |
| Kentucky | — | No white-bagging restriction (2021 HB 48 is a pharmacist-reimbursement law, often misfiled here). |
| Maine | — | No white-bagging restriction (NICA, Feb 2026). |
| Michigan | — | No white-bagging restriction (NICA, Feb 2026). |
| Missouri | — | No white-bagging statute. SB 878 (delivered to the Governor June 2026) — widely tracked as a pending ban — reached the Governor as a pharmacy omnibus whose only drug-payment provision is 340B reimbursement non-discrimination; no clinician-administered-drug sourcing language survived to the final version. |
| Montana | — | No white-bagging restriction (NICA, Feb 2026). |
| Nevada | — | No white-bagging statute. |
| New Jersey | — | PBM laws are not bagging-specific; no clinician-administered-drug statute. |
| North Carolina | — | No enacted law; NC Healthcare Association maintains advocacy resources seeking one. |
| Pennsylvania | — | Act 77 of 2024 bans general PBM mail-order steering but does not address site-of-care dispensing. |
| South Carolina | — | No enacted or notably advanced legislation. |
| South Dakota | — | No enacted or notably advanced legislation. |
| Washington | — | 2024 PBM law doesn't reach clinician-administered drugs; pharmacy-commission exploration has produced no rule. |
| Wisconsin | — | A white-bagging bill failed in committee in 2022; nothing has advanced since. |
| Wyoming | — | No enacted or introduced white-bagging law. |
Five statute citations circulating in other trackers don’t match the enacted texts. Verified against the primary sources:
And one status correction from the June 2026 pass — including to our own earlier read: Missouri’s SB 878, watched across the industry as a pending white-bagging ban, was delivered to the Governor as a pharmacy omnibus (meth-precursor limits, vaccine authority, OTC ivermectin, 340B reimbursement non-discrimination). No clinician-administered-drug sourcing provision survived to the final version, so Missouri is classified “no statute.”
State law is half the picture; the other half is what the national payers’ programs actually bind. The detail most coverage misses is the setting distinction — verified from the payer documents themselves:
UHC’s medication-sourcing protocol (May 2026 revision) binds the hospital-outpatient setting; physician-office buy-and-bill is outside its scope (the all-settings tier covers gene/rare therapies only). N/A in KY, MD, RI. For an office practice this is a site-of-care advantage, not a sourcing risk.
Aetna’s CBM program moves listed drugs (Remicade brand, Ocrevus, Tezspire, Xolair, Evenity) to pharmacy-benefit-only coverage on fully-insured commercial plans — buy-and-bill leaves the medical benefit entirely. Aetna’s own April-2026 documents carve out 12 states where state law keeps these drugs on the medical benefit: AK, AR, GA, LA, MN, MS, ND, OK, RI, TN, TX, VT. Note the biosimilar asymmetry: brand Remicade is listed, but Inflectra, Renflexis and Avsola stay medical-benefit preferred — biosimilar conversion preserves buy-and-bill.
Anthem’s Designated Medical Specialty Pharmacy program (May 2024 revision; CO/GA/IN/KY/MO/NH/OH/WI + CA) binds the hospital-outpatient setting — office practices are out of scope.
Pathwell Specialty (Jan 2026 list) is a benefit design: plans carrying it require a participating provider or in-network specialty pharmacy for listed drugs. Exposure depends on whether the member’s plan includes Pathwell — verify per member, not per payer.
These program reads are encoded in the Optimizer’s carve-out engine and re-verified against the payer documents quarterly. A stale claim here is a denied claim — which is why this page is a tracker with dates, never a live per-payer-per-drug grid.
Payer-mandated white bagging is restricted by enacted law in 22 states as of June 10, 2026 — 11 with bans on mandates (some condition- or specialty-limited) and 11 with partial guardrails. 6 more states have live bills. The map and tables above carry each state's statute citation; the controlling question is always the exact statutory text plus whether the plan is state-regulated.
Generally no. Every state law on this page binds state-regulated (fully-insured) coverage; self-funded ERISA plans — roughly two-thirds of commercial enrollment — are federally preempted and can mandate white bagging even in ban states. That is why a practice's exposure depends on its payer-and-funding mix, not just its address.
White bagging: the payer's designated specialty pharmacy dispenses the drug and ships it to the provider site for administration. Brown bagging: the pharmacy dispenses to the patient, who transports it to the provider — banned more often because of handling risk. Clear bagging: the provider's own affiliated specialty pharmacy dispenses internally — typically unaffected by these statutes.
Three reasons: scope (some count anti-steering or brown-bag-only laws as 'white-bagging laws'), vintage (the most-cited chart is a January 2024 PDF that predates Mississippi, Oklahoma, Rhode Island, Oregon, and Alaska), and miscitation (several circulating statute numbers are simply wrong — see the corrections section above). We classify bans, guardrails, and pending bills separately and cite every statute to its primary text.
The 2024–2026 wave: Alaska (eff. Jan 2025), Rhode Island (eff. Jan 2025), Oregon's oncology-only ban (eff. Jan 2025), Mississippi (eff. July 2025), and Oklahoma (Apr 2024). New Hampshire's bill went to interim study in May 2026. And a June 2026 correction from our own verification pass: Missouri's SB 878 — tracked across the industry as a pending white-bagging ban — reached the Governor's desk as a pharmacy omnibus with no clinician-administered-drug sourcing provision at all.
What white bagging costs in margin terms: every drug page on the trend tracker shows the buy-and-bill economics at stake. How this data is verified: the Data Desk.
carecostoptimizer.com/resources/margin-watch/white-bagging-and-sourcing-mandates. Statute citations verified June 10, 2026. Free to cite with attribution. This page is general information, not legal advice — confirm the controlling text with counsel before acting.The practice X-Ray prices the margin you’d forfeit per drug — your mix, your payers, your state — and shows where the law and the biosimilar escape hatches give you leverage.